Maxim Group’s healthcare analyst Jason Kolbert came out with a research report on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) following the news that the company has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The analyst reiterated a Buy rating with a $2 price target, which implies an upside of 627% from current levels.
Kolbert observed, “We see compelling value ahead in this company across multiple programs. Success with the pivotal program is not being factored into the current valuation by wall street in our opinion nor is the return of Macrilen. In fact we see Macrilen as representing a paradigm shift in the adult growth hormone deficiency (AGHD) marketplace. The current test, insulin tolerance is long and burdensome compared to Macrilen. As such Macrilen could expand the market.”
The analyst concluded, “We see the current Macrilen trial as low risk, high reward. Other near-term catalysts should support and drive valuation.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 0.5% and a 40.3% success rate. Kolbert has a -53.4% average return when recommending AEZS, and is ranked #2010 out of 3688 analysts.